Drugs / AZD8683
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01666613 | Nov 2012 → Mar 2013 | — | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 1 | NCT01584739 | Jun → Nov 2012 | chronic obstructive pulmonary disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT01419600 | Oct 2011 → May 2012 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00979849 | Oct 2009 → Jan 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01708057 | Oct → Dec 2012 | chronic obstructive pulmonary disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT01205269 | Oct → Dec 2010 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD 8683 | “Group 1 - 4, single ascending dose AZD 8683” NCT01419600 ↗ |
| Action | Inhibit | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL3545222 ↗ |
| Route | Inhaled | “Solution for nebulisation, inhaled” NCT00979849 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL3545222 ↗ |